The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

Rong Fan; Nathan De Beule; Anke Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Ken Maes; Karine Breckpot; Kim De Veirman

doi:10.3389/fimmu.2022.1016059

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

Rong Fan, Nathan De Beule, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

36 Downloads (Pure)

Abstract

The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.

Original language	English
Article number	1016059
Number of pages	16
Journal	Frontiers in Immunology
Volume	13
DOIs	https://doi.org/10.3389/fimmu.2022.1016059
Publication status	Published - 11 Oct 2022

Bibliographical note

Funding Information:
This work was supported by Fonds voor Wetenschappelijk Onderzoek (FWO), Wetenschappelijk Fonds Willy Gepts (WFWG), and Strategic Research Programme (SRP48). KDV is a postdoctoral fellow of FWO (12I0921N).

Publisher Copyright:
Copyright © 2022 Fan, De Beule, Maes, De Bruyne, Menu, Vanderkerken, Maes, Breckpot and De Veirman.

Copyright:
Copyright 2022 Elsevier B.V., All rights reserved.

Keywords

MDSCs
hematological malignancies

Access to Document

10.3389/fimmu.2022.1016059Licence: CC BY

88575472Final published version, 1.48 MBLicence: CC BY

Cite this

@article{54e67d22ae8241a38584d00bb4b535db,

title = "The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers",

abstract = "The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.",

keywords = "MDSCs, hematological malignancies",

author = "Rong Fan and {De Beule}, Nathan and Anke Maes and {De Bruyne}, Elke and Eline Menu and Karin Vanderkerken and Ken Maes and Karine Breckpot and {De Veirman}, Kim",

note = "Funding Information: This work was supported by Fonds voor Wetenschappelijk Onderzoek (FWO), Wetenschappelijk Fonds Willy Gepts (WFWG), and Strategic Research Programme (SRP48). KDV is a postdoctoral fellow of FWO (12I0921N). Publisher Copyright: Copyright {\textcopyright} 2022 Fan, De Beule, Maes, De Bruyne, Menu, Vanderkerken, Maes, Breckpot and De Veirman. Copyright: Copyright 2022 Elsevier B.V., All rights reserved.",

year = "2022",

month = oct,

day = "11",

doi = "10.3389/fimmu.2022.1016059",

language = "English",

volume = "13",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. / Fan, Rong ; De Beule, Nathan ; Maes, Anke ; De Bruyne, Elke ; Menu, Eline ; Vanderkerken, Karin ; Maes, Ken ; Breckpot, Karine ; De Veirman, Kim.

In: Frontiers in Immunology, Vol. 13, 1016059, 11.10.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

AU - Fan, Rong

AU - De Beule, Nathan

AU - Maes, Anke

AU - De Bruyne, Elke

AU - Menu, Eline

AU - Vanderkerken, Karin

AU - Maes, Ken

AU - Breckpot, Karine

AU - De Veirman, Kim

N1 - Funding Information: This work was supported by Fonds voor Wetenschappelijk Onderzoek (FWO), Wetenschappelijk Fonds Willy Gepts (WFWG), and Strategic Research Programme (SRP48). KDV is a postdoctoral fellow of FWO (12I0921N). Publisher Copyright: Copyright © 2022 Fan, De Beule, Maes, De Bruyne, Menu, Vanderkerken, Maes, Breckpot and De Veirman. Copyright: Copyright 2022 Elsevier B.V., All rights reserved.

PY - 2022/10/11

Y1 - 2022/10/11

N2 - The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.

AB - The success of immunotherapeutic approaches in hematological cancers is partially hampered by the presence of an immunosuppressive microenvironment. Myeloid-derived suppressor cells (MDSC) are key components of this suppressive environment and are frequently associated with tumor cell survival and drug resistance. Based on their morphology and phenotype, MDSC are commonly subdivided into polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC), both characterized by their immunosuppressive function. The phenotype, function and prognostic value of MDSC in hematological cancers has been intensively studied; however, the therapeutic targeting of this cell population remains challenging and needs further investigation. In this review, we will summarize the prognostic value of MDSC and the different attempts to target MDSC (or subtypes of MDSC) in hematological cancers. We will discuss the benefits, challenges and opportunities of using MDSC-targeting approaches, aiming to enhance anti-tumor immune responses of currently used cellular and non-cellular immunotherapies.

KW - MDSCs

KW - hematological malignancies

UR - http://www.scopus.com/inward/record.url?scp=85140361053&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2022.1016059

DO - 10.3389/fimmu.2022.1016059

M3 - Article

C2 - 36304465

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 1016059

ER -

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy

Cite this

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Projects

SRP84: SRP-Onderzoekszwaartepunt: PACT: multi-omics Profiling of T cells to improve Adoptive Cell Therapy

Cite this